Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics In Surgery ›› 2023, Vol. 23 ›› Issue (04): 343-346.DOI: 10.3969/j.issn.1009-976X.2023.04.010

• Case Report • Previous Articles     Next Articles

Adenoid cystic carcinoma of breast: two cases and review of literature

WU Xiao-yong1, YAN Xue-min1, ZHANG Jia-yi1, WEN Jin-xu2, ZHU Jia1, WANG Yue-xin3   

  1. 1. Graduate School of North China University of Science and Technology, Tangshan 06300, China;
    2. Graduate School of Hebei Medical University, Shijiazhuang 050011, China;
    3. Department of Glandular Surgery, Hebei Provincial People′s Hospital, Shijiazhuang 050051, China;
  • Contact: WANG Yue-xin, Wangyx886@sina.com

乳腺腺样囊性癌两例并文献复习

武霄勇1, 闫学敏1, 张佳谊1, 文锦旭2, 祝嘉1, 王跃欣3,*   

  1. 1.华北理工大学研究生学院, 河北唐山 063000;
    2.河北医科大学研究生学院,石家庄 050011;
    3.河北省人民医院腺体外科, 石家庄 050051
  • 通讯作者: *王跃欣,Email:Wangyx886@sina.com

Abstract: Objective To report two rate cases of adenoid cystic carcinoma of the breast (ACCb). Methods Clinical data of 2 patients diagnosed with ACCb admitted to Hebei Provincial People′s Hospital in 2018 and 2020 were retrospectively analyzed. Results The ages of the two patients were 78 and 56 years old respectively, follow-ups were 39 and 12 months respectively. No recurrence and metastasis were found. Conclusion ACCb is a rare triple-negative breast cancer, its imaging and signs are untypical, and it is easy to be misdiagnosed. The diagnosis of adenoid cystic carcinoma mainly depends on cell morphology and immunohistochemistry. However, adenoid cystic carcinoma is a type of triple negative breast cancer with a relatively good prognosis.

Key words: breast tumors, triple-negative breast cancer, adenoid cystic carcinoma, clinicopathological features, immunohistochemistry

摘要: 目的 提升对乳腺腺样囊性癌(ACCb)的认识。方法 回顾性分析2018和2020年河北省人民医院收治且确诊为ACCb的2例患者的临床资料。结果 2例女性患者年龄分别为78岁和56岁,随访时间分别为12个月和39个月均无复发转移。结论 ACC为罕见的一种三阴性乳腺癌,它的影像学表现和患者的体征都不典型,容易误诊,确诊主要依赖细胞形态学和免疫组织化学,是三阴性乳腺癌中预后相对较好的类型。

关键词: 乳腺肿瘤, 三阴性乳腺癌, 腺样囊性癌, 临床病理特征, 免疫组织化学

CLC Number: